Physician profile
Nelson P Tamala
NPI 1043762453
$4,578.65
in general payments reported to CMS, 2019-2025
10 companies · $1,071 in 2025
The $1,071 reported for 2025 was more than what 88% of Family Health providers received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $562 · 2022: $839 · 2023: $995 · 2024: $1,111 · 2025: $1,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,068 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,068.37 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,594.22 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $1,258.65 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $503.96 | 2021-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $384.72 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $271.44 | 2022-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $251.92 | 2021-2024 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $122.19 | 2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $112.84 | 2025 | Nuplazid |
| Lundbeck LLC | $53.97 | 2022-2024 | Rexulti |
| Indivior INC. | $24.74 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Tamala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.